Beam Therapeutics (NASDAQ:BEAM) shared promising results from the early stage trial of its genetically modified cell therapy, BEAM-101, for the treatment of severe sickle cell disease. The data ...
Beam Therapeutics announced positive updates on its BEAM-101 treatment for sickle cell disease (SCD) from the BEACON Phase 1/2 clinical trial, with results presented at the European Hematology ...
What you need to know: Myths and associating the condition with witchcraft are hampering fight against the disease, with many people with the condition shying away from openly seeking health services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results